Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
SCHOTT Pharma and KORU Medical Systems (NASDAQ: KRMD) announced a collaboration to advance large-volume subcutaneous infusion. KORU Medical, known for its Freedom Infusion System, and SCHOTT Pharma, known for its TOPPAC® prefillable polymer syringes, aim to optimize drug delivery in large-volume subcutaneous infusion markets. The collaboration seeks to simplify and de-risk drug administration for both healthcare professionals and patients. The focus is on therapies requiring large volumes and recurring dosing, such as chronic diseases and cancer. Their joint solution promises improved time-to-market for infusion therapies and a streamlined drug development process. SCHOTT's prefillable syringes, available in 5mL to 50mL formats, are compatible with KORU's Freedom System, enhancing ease of use and reducing administration errors.
- Collaboration between SCHOTT Pharma and KORU Medical Systems may accelerate time-to-market for large-volume subcutaneous infusion therapies.
- The joint solution simplifies subcutaneous drug administration, making it safer and easier for both healthcare providers and patients.
- SCHOTT Pharma’s prefillable syringes, available in large volumes up to 50mL, meet the market needs for high-viscosity drugs.
- Reduction in administration errors due to prefilled syringes reduces the complexity of drug delivery.
- The partnership may streamline the pharmaceutical drug development process.
- The collaboration addresses the growing need for subcutaneous drug infusion for chronic diseases and cancer treatments.
- No specific financial details or revenue projections from the collaboration were provided.
- Potential risks are associated with dependency on the success of the combined technologies in a real-world setting.
- The focus on transitioning from vials to prefillable syringes may incur initial costs and require significant operational changes.
Insights
The collaboration between SCHOTT Pharma and KORU Medical Systems is a significant step for the medical technology industry, particularly for large volume subcutaneous drug delivery. The introduction of prefillable polymer syringes in conjunction with KORU's Freedom Infusion System offers an enhanced and simplified drug administration process, which is important for chronic disease therapies that require large volumes and recurrent doses.
The most immediate impact of this partnership is the reduction of manual steps in drug administration. This can significantly lower the risk of administration errors, a common concern with complex dosing regimens. This is particularly beneficial in home care settings where patients might not have professional medical training. This collaboration is expected to drive down costs associated with training healthcare providers and patients and also reduce the risk of human error.
Another important aspect to consider is the potential acceleration in the time-to-market for new therapies. Streamlining the drug delivery process can help pharmaceutical companies navigate regulatory hurdles more efficiently. This could be a competitive advantage for drugs that need to reach patients quickly.
However, there are also potential drawbacks. The reliance on specific technologies could make the process more rigid. If any component of the system faces a supply chain issue, it could disrupt the entire delivery process. Additionally, while the system reduces steps, it also centralizes dependence on these technologies, which could bring about higher costs for maintenance and replacement.
From a market perspective, the collaboration between SCHOTT Pharma and KORU Medical Systems is poised to strengthen their positions in the large volume subcutaneous infusion market. This market is growing rapidly due to the rising prevalence of chronic diseases and the increasing preference for home-based treatments.
The combination of SCHOTT's prefillable syringes and KORU's infusion systems offers a differentiated product that can attract a significant share of the market. These systems not only promise ease of use but also address the needs of treatments that require higher drug viscosities and volumes, making them suitable for conditions like cancer and immunological disorders. Such innovations are likely to be well-received by both healthcare providers and patients, especially in markets where self-administration is becoming more common.
However, the market adoption of these technologies will depend on several factors, including pricing strategies, regulatory approvals and the readiness of healthcare systems to integrate these advanced solutions. Competitors in the subcutaneous drug delivery market might also accelerate their development efforts, increasing the competitive pressure.
In the long term, if this collaboration proves successful, it could set a new industry standard for large volume subcutaneous infusions. This would not only benefit the companies involved but also potentially make such treatments more accessible and efficient for patients globally.
- The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”) and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC® prefillable polymer syringes (PFS), intend to collaborate on optimization of drug delivery in the large volume subcutaneous infusion market.
- When combined with pharma therapies, the joint offering will optimize the ability to administer large volumes of medication subcutaneously and streamline the pharmaceutical drug development process.
- Application of these technologies provide the potential to simplify and de-risk delivery of large volume subcutaneous therapies in both administration by healthcare professionals in a clinic setting or patient self-administration in the home setting.
MAINZ,
Andreas Reisse went on to say, “As these two technologies have already demonstrated their ability to solve the subcutaneous immunoglobulin (SCIg) therapy market leader’s transition from vials to PFS, pharmaceutical companies can take comfort in a de-risked development pathway with KORU Medical’s commercialized Freedom System and SCHOTT TOPPAC® ready-to-use prefillable polymer syringes.”
Linda Tharby, President and CEO of KORU Medical Systems said, “With the shift currently happening in the SCIg market from vials to PFS, patients and health care professionals have already begun utilizing our system in conjunction with SCHOTT Pharma prefillable syringes. As the syringes come prefilled with the exact drug dosage and are capable of being delivered via the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, there are no vial preparation steps needed. This is both a simpler process for patients and reduces the risk of administration errors.” Linda Tharby went on to say, “KORU Medical is very excited to partner with SCHOTT Pharma to simplify drug development for our pharmaceutical partners and facilitate greater success of large volume administration for our patients.”
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its novel therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including but not limited to those relating to the success of the partnership and patient acceptance of the combination product. Actual results may differ materially from these statements due to potential risks and uncertainties such as, among others, success of the feasibility study, agreement with the pharmaceutical manufacturer with respect to customization of the system, successful development of the system, obtaining regulatory clearances, and by those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of June 5, 2024. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605555897/en/
Schott Pharma Press Contact:
Joana Kornblum
Joana.Kornblum@schott.com
+49 151 29223552
Koru Medical Investor Contact:
Louisa Smith
investor@korumedical.com
Source: KORU Medical Systems
FAQ
What collaboration did SCHOTT Pharma and KORU Medical Systems announce?
What is the significance of the collaboration between SCHOTT Pharma and KORU Medical Systems?
How does the collaboration between SCHOTT Pharma and KORU Medical Systems impact drug delivery?
What are the target applications for the SCHOTT Pharma and KORU Medical Systems collaboration?
What are the benefits for patients using the joint solution from SCHOTT Pharma and KORU Medical Systems?
What sizes of prefillable syringes does SCHOTT Pharma offer for this collaboration?
What products from KORU Medical Systems are involved in this collaboration?
How does the collaboration between SCHOTT Pharma and KORU Medical Systems benefit pharmaceutical companies?
